[EN] HBED PRODRUGS AND USE THEREOF<br/>[FR] PROMÉDICAMENTS DE HEBD ET LEUR UTILISATION
申请人:UNIV OF FLORIDA RES FOUND INCORPPORATED
公开号:WO2017040653A1
公开(公告)日:2017-03-09
The present invention provides N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid (HBED) prodrugs of Formula (I), (II), and (III), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, and polymorphs for treatment or prevention of diseases that are associated with oxidative stress and/or excess metal (e.g. iron). The present invention further provides HBED prodrugs of Formula (I), (II), and (III), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, and polymorphs for the treatment and/or prevenation of macular degeneration. The provided HBED prodrugs may have improved oral availability and/or brain penentration compared to HBED.
本发明提供了式(I)、(II)和(III)的N,N'-双(2-羟基苯甲基)乙二胺-N,N'-二乙酸(HBED)前药,以及与氧化应激和/或过量金属(例如铁)相关的疾病的治疗或预防的药用盐、互变异构体、立体异构体、溶剂合物、水合物和多晶形式。本发明还提供了式(I)、(II)和(III)的HBED前药,以及用于治疗和/或预防黄斑变性的药用盐、互变异构体、立体异构体、溶剂合物、水合物和多晶形式。所提供的HBED前药可能比HBED具有改善的口服可用性和/或脑透过性。